131 completed, 65 terminated, 57 active not recruiting, 33 recruiting. 324 Phase 1, 134 Phase 2.
Follow Opdivo: new trials by email Literature Review of Opdivo trials Research Report on Opdivo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab - Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2026-10-28 | 2026-10-30 |
| Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma Bmab1700, Opdivo - Melanoma | Phase 1 | Recruiting | Biocon Biologics UK PLC | 120 | 2026-09-09 | 2026-11-06 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases | Phase 1 / Phase 2 | Recruiting | Melanoma and Skin Cancer Trials Limited | 46 | 2026-08-31 | 2026-10-13 |
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas Pazopanib, Trabectedin, Ipilimumab - Soft Tissue Sarcomas | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-12 | 2026-08-06 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody - Prostate Cancer Patients, Non-castrate Prostate Cancer | Phase 1 | Recruiting | University of Wisconsin, Madison | 14 | 2026-03-03 | 2026-03-11 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-12 | 2026-08-11 |
| Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma | Phase 1 | Suspended | Washington University School of Medicine | 18 | 2026-01-05 | 2026-09-04 |
| Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma HLX13, Yervoy, OPDIVO - Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Shanghai Henlius Biotech | 246 | 2025-11-25 | 2026-03-16 |
| Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-28 | 2025-08-07 | |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors BMS-986488, Adagrasib, Cetuximab - Advanced Malignant Tumors | Phase 1 | Recruiting | Bristol-Myers Squibb | 437 | 2025-03-25 | 2026-07-29 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors BMS-986507, Osimertinib, Pembrolizumab - Lung Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 416 | 2025-02-04 | 2026-09-23 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors BMS-986484, Nivolumab, Oxaliplatin - Advanced Solid Tumors | Phase 1 | Active not recruiting | Bristol-Myers Squibb | 213 | 2024-10-10 | 2026-04-17 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
Showing 20 of 324. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (52) · Melanoma (48) · Carcinoma, Renal Cell (38) · Neoplasms (28) · Neoplasm Metastasis (26) · Colorectal Neoplasms (25) · Carcinoma, Hepatocellular (23) · Lung Neoplasms (19) · Squamous Cell Carcinoma of Head and Neck (19) · Carcinoma, Transitional Cell (14) · Pancreatic Neoplasms (14) · Breast Neoplasms (12) · Ovarian Neoplasms (12) · Stomach Neoplasms (12) · Triple Negative Breast Neoplasms (12)
Bristol-Myers Squibb (41) · National Cancer Institute (NCI) (27) · M.D. Anderson Cancer Center (23) · H. Lee Moffitt Cancer Center and Research Institute (10) · City of Hope Medical Center (9) · Washington University School of Medicine (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Emory University (7) · Mayo Clinic (6) · Jonsson Comprehensive Cancer Center (5) · Northwestern University (5) · St. Petersburg State Pavlov Medical University (5) · Celgene (4) · Dana-Farber Cancer Institute (4) · Sumitomo Pharma America, Inc. (4)
United States (271) · Canada (33) · Australia (32) · Spain (29) · France (23) · Italy (20) · Belgium (15) · Japan (14) · Netherlands (14) · United Kingdom (14) · Germany (12) · Argentina (11) · Chile (10) · Poland (10) · Russia (7)
Sumanta K Pal (4) · Boris V Afanasyev, Ph.D (2) · Catherine S Diefenbach (2) · Curtis Chin, MD (2) · David Bond, MD (2) · Eric Jonasch, MD (2) · Erlinda M Gordon, MD (2) · Evan J Lipson (2) · Helen Heslop, MD (2)
PMID 31401903, PMID 34272087, PMID 34385708, PMID 39462179, PMID 22590666, PMID 24089446, PMID 25482239, PMID 26773716, PMID 27269947, PMID 27410923, PMID 27528724, PMID 29257710, PMID 29490632, PMID 29628312, PMID 29692997, PMID 31105267, PMID 31400961, PMID 31538815, PMID 31563517, PMID 32192573, PMID 32303612, PMID 32478814, PMID 32489249, PMID 32503469, PMID 32503950, PMID 32508818, PMID 32616557, PMID 32853585, PMID 32915679, PMID 33002543, PMID 33046870, PMID 33062947, PMID 33064988, PMID 33148673, PMID 33203665, PMID 33277223, PMID 33294862, PMID 33387490, PMID 33507454, PMID 33535600, PMID 33608377, PMID 33677480, PMID 33720354, PMID 33757459, PMID 33786583, PMID 33892407, PMID 33909232, PMID 33963014, PMID 34347542, PMID 34543871
2018 (11), P30CA033572 (8), 2016 (5), 2017 (5), P30CA060553 (5), P30CA138292 (5), UM1CA186691 (4), 2015 (3), 2023 (3), P30CA014089 (3), UM1CA186689 (3), 2019 (2), 2025 (2), P30CA006516 (2), P30CA015704 (2)